First amyloid β1‐42 certified reference material for re‐calibrating commercial immunoassays
Sébastien Boulo, Julia Kuhlmann, Ulf Andréasson, Britta Brix, Iswariya Venkataraman, Victor Herbst, Sandra Rutz, Ekaterina Manuilova, Manu Vandijck, Filip Dekeyser, Maria Bjerke, Josef Pannee, Charoud-Got Jean, Guy Auclair, Mazoua Stephane, Gregor Pinski, Stefanie Trapmann, Heinz Schimmel, Hendrik Emons, Milena Quaglia, Erik Portelius, Magdalena Korecka, Leslie M. Shaw, Mary E. Lame, Erin Chambers, Hugo Vanderstichele, Erik Stoops, Andreas Leinenbach, Tobias Bittner, Rand Jenkins, Vesna Kostanjevečki, Piotr Lewczuk, Johan Gobom, Henrik Zetterberg, Ingrid Zegers, Kaj Blennow
Abstract
Abstract Introduction Reference materials based on human cerebrospinal fluid were certified for the mass concentration of amyloid beta (Aβ)1‐42 (Aβ 42 ). They are intended to be used to calibrate diagnostic assays for Aβ 42 . Methods The three certified reference materials (CRMs), ERM‐DA480/IFCC, ERM‐DA481/IFCC and ERM‐DA482/IFCC, were prepared at three concentration levels and characterized using isotope dilution mass spectrometry methods. Roche, EUROIMMUN, and Fujirebio used the three CRMs to re‐calibrate their immunoassays. Results The certified Aβ 42 mass concentrations in ERM‐DA480/IFCC, ERM‐DA481/IFCC, and ERM‐DA482/IFCC are 0.45, 0.72, and 1.22 μg/L, respectively, with expanded uncertainties ( k = 2) of 0.07, 0.11, and 0.18 μg/L, respectively. Before re‐calibration, a good correlation (Pearson's r > 0.97), yet large biases, were observed between results from different commercial assays. After re‐calibration the between‐assay bias was reduced to < 5%. Discussion The Aβ 42 CRMs can ensure the equivalence of results between methods and across platforms for the measurement of Aβ 42 .